AUROBINDO PHARMA |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,131 INR | +2.53% |
|
+4.07% | +4.36% |
Presentation Operator MessageOperator (Operator)Welcome to Aurobindo Pharma Q3 FY '24 Earnings...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Aurobindo Pharma specializes in the research, development, manufacturing and marketing of active pharmaceutical ingredients and generic pharmaceuticals. The group's activity is organized around 2 product families :
- generic drugs: for the treatment of neurological, cardiovascular, viral, gastroenterological, ophthalmologic and chronic diseases;
- active pharmaceutical ingredients.
At the end of March 2018, the group operated 23 production sites in India (19), the United States (3) and Brazil.
Net sales are distributed geographically as follows: India (12%), the United States (46.5%), Europe (31.2%) and other (10.3%).
Sector
Pharmaceuticals
Calendar
2024-05-29
- Q4 2024 Earnings Release
Trading Rating
Investor Rating
ESG Refinitiv
B
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
24
Last Close Price
1,131
INR
Average target price
1,190
INR
Spread / Average Target
+5.23%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +4.36% | 7.95B | |
| +25.83% | 661B | |
| +27.00% | 566B | |
| -6.76% | 352B | |
| +20.34% | 332B | |
| +3.00% | 283B | |
| +13.09% | 231B | |
| +5.46% | 200B | |
| -9.61% | 195B | |
| -6.26% | 145B |
- Stock Market
- Equities
- AUROPHARMA Stock
- News Aurobindo Pharma
- Transcript : Aurobindo Pharma Limited, Q3 2024 Earnings Call, Feb 12, 2024
